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Genetic-Code-Expansion Strategies for Vaccine
Development
Jelle A. Fok[a] and Clemens Mayer*[a]
Abstract: By providing long-term protection against infectious
diseases, vaccinations have significantly reduced death and
morbidity worldwide. In the 21st century, (bio)technological
advances have paved the way for developing prophylactic
vaccines that are safer and more effective as well as enabling
the use of vaccines as therapeutics to treat human diseases.
Here, we provide a focused review of the utility of genetic code
expansion as an emerging tool for the development of vaccines.
Specifically, we discuss how the incorporation of immunogenic
noncanonical amino acids can aid in eliciting immune
responses against adverse self-proteins and highlight the
potential of an expanded genetic code for the construction of
replication-incompetent viruses. We close the review by discus-
sing the future prospects and remaining challenges for the
application of these approaches in the development of both
prophylactic and therapeutic vaccines in the near future.
1. Introduction
The routine vaccination of large populations was the single
most effective medical intervention in reducing death and
morbidity in the 20th century.[1] For example, pioneering work
on vaccines resulted in the eradication of small pox[2] and the
reduction of polio cases from 350.000 in 1988 to 66 in 2019.[3]
Today, routine vaccinations continue to protect millions each
year against a growing number of infectious diseases. Never-
theless, recent and ongoing pandemics such as those caused
by H1N1 influenza A virus,[4] human immunodeficiency virus
(HIV),[5] and severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)[6] serve as a stark reminder that advances in
vaccine development remain highly relevant. Such efforts will
also be crucial for creating more efficient vaccines that protect
against infectious diseases, such as malaria or tuberculosis,[7]
and aid efforts in which vaccines are not used prophylactically
but as the primary form of treatment for a disease (=
immunotherapy).[8]
Scientific and (bio)technological innovations have repeat-
edly enabled the development of effective vaccines.[9] Many of
the techniques for vaccine production and development that
have been in use for decades (e. g., serial passaging in vitro or
through abnormal hosts)[10] continue to remain relevant today.
However, new approaches based on technologies that have
become available over the past decades are being explored for
the production of safe and effective vaccines.[11] Herein, we
focus on genetic code expansion[12] as an innovative tool for the
development of prophylactic and therapeutic vaccines. With a
broad chemical biology audience in mind, we first provide
accessible introductions to immunology and relevant genetic
code expansion strategies, before discussing protein-based
vaccines, live-attenuated viruses and providing a general out-
look on the utility of an expanded genetic code for the
development of vaccines in the future.
1.1. A hitchhiker’s guide to vaccine immunology
Prophylactic vaccinations aim to provide long-term protection
against pathogens (i. e., immunological memory) through
activation of the adaptive immune system.[13] Thus, vaccines
function by inducing the production of effector cells or
molecules that are capable of neutralizing pathogens by
controlling their replication or inactivating their toxic compo-
nents. Depending on the type of vaccine, mode of delivery and
additives used, the exact mechanisms by which protection is
achieved will differ.[14] Here we focus on the induction of a T
cell-dependent humoral immune response, that is the secretion
of specific antibodies and the formation of memory B cells
against pathogen-specific antigens upon immunization.[15] For
an in-depth review of more complex pathways that result in the
secretion of antibodies in mucosal membranes (mucosal
immunity) or the production of cytotoxic T lymphocytes (cell-
mediated immunity), the reader is referred to specialized
literature.[16]
Overall, the main steps (numbered 1–15 in Figure 1) toward
acquiring vaccine-induced humoral immunity are: stimulation
of the innate immune system, leading to local inflammation
and transport of antigens to the draining lymph nodes (dLNs;
1–4); activation of antigen specific T and B cells, upon which
the latter undergoes affinity maturation and differentiation into
antibody-producing plasma B cells (5–12); and antibody
secretion in the blood (and tissue) and build-up of immuno-
logical memory (13–15).[13,15]
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Stimulation of the innate immune system is triggered by (1)
injecting a vaccine that contains a mixture of weakened
pathogens or pathogen-specific antigen(s) and immune re-
sponse-boosting additives (= adjuvants). The resulting local
inflammation leads, amongst others, to recruitment of dendritic
cells, which take up the antigens and are subsequently
activated (2). The activated dendritic cells undergo changes in
their morphology and surface receptors, facilitating the pre-
sentation of antigens (3) and inducing their migration to the
dLNs (4). In response to these antigen-presenting cells entering
the dLNs, naïve antigen-specific CD4+ T cells undergo activation
and differentiate to helper T cells (5, 6). In parallel, activation
takes place of naïve B cells that feature surface antibodies with
(weak) affinity for antigens drained from the site of infection,
triggering a multistep process that results in the display of
antigens on the surface of activated B cells (7). Subsequently,
the interaction between antigen-presenting activated B cells
and antigen-specific helper T cells (8) induces B-cell prolifer-
ation and their differentiation into plasma B cells (9). The low-
affinity antibodies secreted by these plasma cells typically
appear in the bloodstream within a few days after the
immunization (10). In a slower process, the interaction between
activated helper T and B cells also triggers the generation of a
geminal center (11), where B cells undergo massive clonal
expansion and affinity maturation (12). In this fine-tuning
process, B cells displaying high affinity antibodies are selected
and subsequently differentiate either into memory B cells (13)
or to long lived plasma cells. The latter enter the bloodstream
and tissues where they secrete large amounts of high affinity
antibodies (14). Lastly, a few of these plasma cells migrate
toward survival niches (15), which are mostly located in the
bone marrow, from which they provide long-term production
of antibodies.
Depending on the type of vaccine and the immunological
memory generated, prevention against infectious diseases can
be short-term or last lifelong.[17] Among the different types of
vaccines available, weakened live pathogens often elicit a
robust immune response, although safety concerns can limit
their applicability (e. g., for immunocompromised patients).[18]
Conversely, vaccines based on inactivated pathogens are safer,
but often require repeated administration of booster doses to
prolong protection. Similar trade-offs between safety and
efficiency are encountered for well-defined vaccines based on
subunits of pathogens (i. e., proteins or polysaccharides)[19] or
those applied for therapeutic applications in immunotherapy.[8]
As mentioned before, biotechnological innovations play a key
role in overcoming these limitations, with this review focusing
on the utility of genetic code expansion strategies for the
development of improved prophylactic and therapeutic vac-
cines.
1.2. The ins and outs of genetic code expansion
“Genetic code expansion” is an umbrella term for strategies that
enable the ribosomal incorporation of noncanonical amino
acids (ncAAs) into peptides or proteins of interest. These
strategies facilitate ncAA incorporation either through the
global reassignment of sense codons or the suppression of
nonsense codons (i. e., stop or quadruplet codons).[12,20] The
latter strategy has proven particularly powerful, as it allows for
site-selective incorporation of the non-native building block.
Faithful and efficient expansion of the genetic code by
suppression of in-frame nonsense codons in vivo requires three
principal components: 1) a metabolically stable, nontoxic ncAA
that is readily taken up by the target organism (= bioavail-
ability); 2) a reassigned nonsense codon in the gene of interest,
with the amber stop codon (UAG) or quadruplet codons being
the preferred choices; and 3) an orthogonal translation system
(OTS), consisting of an aminoacyl tRNA synthetase (aaRS)/tRNA
pair, which exclusively recognizes the ncAA. In this context,
orthogonality refers to the fact that none of the OTS
components interact with endogenous amino acids, aaRSs or
tRNAs and vice versa.
Engineering OTSs for expanding the genetic code of
prokaryotes and eukaryotes typically starts from existing aaRS/
tRNA pairs from archaea, which are poorly recognized by
prokaryotic and eukaryotic translation components, thereby
providing an initial level of orthogonality.[21] Next, the tRNA
anticodon is mutated to the desired sequence (e. g., CUA for the
reverse-complement of the UAG amber stop codon) and, if
necessary, its orthogonality can be improved by consecutive
rounds of positive (and negative) selection. Lastly, the substrate
binding pocket of the aaRS is subjected to site-directed
mutagenesis and variants are selected that allow the incorpo-
ration of the ncAA of interest. These engineering efforts
typically result in selective and efficient OTSs that load a ncAA
onto an orthogonal tRNA, with the charged tRNAs subsequently
being recruited to the ribosome, where in-frame UAG stop
codons in mRNAs can be suppressed (Figure 2).
Although low read-through efficiencies typically result in
limited protein yields, the suppression of nonsense codons has
enabled the incorporation of more than 150 ncAAs into
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proteins of interest in a variety of organisms.[12] For the majority,
these efforts have focused on introducing ncAAs harboring
functional groups that enable site-selective protein modification
and/or aid in elucidating, altering or regulating protein
function.[22] More recently, ncAAs featuring uniquely reactive
side chains have also been employed to select cyclic peptides
with novel ring architectures, design enzymes with new-to-
nature reactivities and create organisms whose lives are
dependent on these non-native building blocks (= synthetic
auxotrophy).[23] In this minireview, we add to this growing list of
applications that repurpose OTSs by highlighting their utility for
vaccine development.
2. Protein-Based Vaccines
The immune system of mammals is finely tuned to discriminate
between endogenous (self) proteins and those from potentially
pathogenic foreign entities (nonself).[24] Tolerance to self-
proteins is primarily achieved through the inactivation of self-
reactive B and T cells during their development, a process that
is crucial to prevent misguided attacks of the immune system.[25]
The consequences of inadvertently breaking this self-tolerance
is readily apparent by the adverse effects of >80 known
autoimmune diseases.[26] Nevertheless, breaking self-tolerance
can also be desirable, for example for cancer immunotherapy,[8]
or for treating diseases caused the by adverse actions of self-
proteins, such as chronic inflammations and osteoporosis.
However, eliciting strong effector mechanisms (e. g., neutraliz-
ing antibodies) against adverse self-proteins remains challeng-
ing. Intentionally breaking self-tolerance typically relies on
immunization with modified self-proteins to elicit antibodies
that are selective for both the modified and the parent self-
protein.[27] Although such cross-reactive immune responses to
adverse self-proteins have been induced by introducing foreign
T-helper cell epitopes into chimeric antigens or by extensive
chemical derivatization of self-antigens, the design of effective
immunotherapeutics remains a slow process.
In contrast to nonselective chemical modification or the
introduction of epitopes which can disrupt protein folding,
genetic code expansion offers a controlled means to modify
therapeutically relevant proteins. For breaking self-tolerance,
nitrated or sulfonated ncAAs are of particular interest. In
addition of these oxidative stress-induced modifications in self-
proteins being associated with the onset of a number of
autoimmune diseases,[28] nitroaryl groups have also been used
as highly immunogenic hapten-molecules that induce a strong
immune response when attached to proteins.[29] Although not
fully understood, the molecular basis for recognition of nitroaryl
groups by the immune system is typically attributed to the
interactions of the electron-deficient π systems with tryptophan
and tyrosine residues that are common in B- or T-cell receptors.
Thus, the ncAAs p-nitro-l-phenylalanine (pNO2Phe), 3-nitro-l-
tyrosine (3NO2Tyr) and p-sulfo-l-phenylalanine (SO3Tyr) can be
considered immunogenic amino acids (Figure 3A). Indeed,
injection of proteins of interests featuring these immunogenic
ncAAs has proven a surprisingly straightforward strategy to
produce high-titer of antibodies that were cross-reactive to the
wild-type protein (Figure 3B). Here, we will focus on studies
performed on the murine tumor necrosis factor-α (mTNF-α) and
the murine receptor activator of nuclear factor-k B ligand
(mRANKL).
2.1. Breaking mTNF-α self-tolerance in mice
TNF-α is a multifunctional cytokine that plays an important role
in the acute phase of inflammation or infection and has been
identified as a clinical target for treatment of multiple
inflammatory diseases, such as Crohn’s disease and rheumatoid
arthritis.[30] To elucidate its role and function in these processes,
studying murine TNF-α in mouse models has proven partic-
ularly useful. For example, mTNF-α-deficient mice are viable
and do not show an apparent phenotype, thus indicating that
immunization against this self-protein would not have adverse
effects.[31] To test the protective effect of eliciting immunolog-
ical memory against mTNF-α, mice are typically subjected to a
lipopolysaccharide (LPS) challenge. The injection of bacterial
LPSs triggers the production and subsequent release of high-
levels of mTNF-α, which induces a potentially lethal septic
shock.[32] However, the presence of cross-reactive antibodies
against the self-protein in challenged mice results in the
breakdown of released mTNF-α, thereby decreasing the severity
of the induced shock.[33]
To test the utility of genetic code expansion for eliciting
antibodies against self-proteins, Schultz and co-workers pro-
duced a series of mTNF-α variants, in which surface-exposed
residues were mutated to immunogenic amino acids (Fig-
ure 3D).[34] Immunization of mice with these variants yielded
antibodies against the mutant protein, while – in accordance
with self-tolerance – attempts at immunization with wild-type
mTNF-α or with variants featuring somatic mutations failed to
elicit a significant immune response. Notably, the ability of
ncAA-bearing mTNF-α variants to generate cross-reactive anti-
bodies against the self-protein upon immunization was depend-
ent on the site of mutation (Figure 3D). Specifically, variants
featuring immunogenic ncAAs at positions Lys11 or Tyr86 gave
rise to high levels of antibodies cross-reactive to wild-type
Figure 2. Schematic depiction of genetic code expansion by suppression of
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mTNF-α. Encouragingly, the antibody titers in mice were found
to be sustained at >80 % for at least 40 weeks after
immunization, signifying the potential for inducing persistent
immunity against the self-protein. Lastly, the protective poten-
tial of immunization with ncAA-bearing mTNF-α variants was
evaluated by the previously outlined LPS challenge model.
Whereas mice that received sham injections or vaccines
containing wild-type protein succumbed quickly after the
challenge (survival rate of 12.5 % after 3 days), immunization
with pNO2Phe11- or pNO2Phe86-mTNF-α provided substantial
levels of protection (Figure 3E). A survival rate of >87.5 % for
these variants attested on the ability to elicit cross-reactive
antibodies that are effective in vivo.
A follow-up study by Ramirez-Montagut and co-workers
aimed to shed light on the mechanism by which incorporation
of immunogenic ncAAs into mTNF-α results in the formation of
antibodies with cross-reactivity for wild-type proteins.[35] One
key insight this study revealed was that mice with different
genetic backgrounds responded differently to the immunization
with modified proteins. For example, while pNO2Phe11mTNF-α
was immunogenic in C57BL/6 mice (see above), the same
mutant protein failed to elicit a significant antibody response in
FVB/N mice. One marked difference with respect to immune
response between these two mouse strains is located in genes
that encode for major histocompatibility complex (MHC) class II
molecules. In the humoral immune response (see Introduction),
these molecules are responsible for antigen-presentation by
dendritic or B cells, thus facilitating interaction of those cells
with naïve and antigen-specific CD4+ T cells.[13,15,36] Class II MHC
genes are known to be highly polymorphic and certain genetic
variations in these genes are linked to predisposition for
autoimmune disease and responsiveness to immunization.[37]
Critically, vaccination with pNO2Phe11mTNF-α proved only
effective in mice that featured the H-2b haplotype, while mice
with a different haplotype or featuring MHC class II molecules
with only three amino acids mutations responded weakly or not
at all to the same immunization regime. Isolated CD4+ T cells
from H-2b mice immunized with pNO2Phe11mTNF-α proved to
undergo activation when presented with peptide antigens that
featured pNO2Phe but failed to do so in response to the wild-
type peptide epitope. In comparison CD4+ T cells isolated from
mice featuring a different haplotype or mutated MHC-class II
molecules did not undergo activation in presence of either the
wild-type or pNO2Phe-containing peptide epitope. Together,
these results are consistent with 1) the negative selection of
autoreactive T-cells in the thymus[38] and 2) ncAA-incorporation
generating modified (neo-)epitopes that can activate T cells,
thus promoting a T cell-dependent immune response. There-
fore, a plausible mechanism for immunization with proteins
featuring immunogenic ncAAs involves the activation of CD4+
T cells by these neo-epitopes being presented on MHC class II
molecules on B cells, triggering clonal proliferation of antigen-
specific B cells and the subsequent production of antibodies
that are cross-reactive to the wild-type protein.
Lastly, immunization with mTNF-α variants featuring
3NO2Tyr or SO3Phe in position Lys11 proved to follow the same
mechanism. This observation is notable as these ncAAs are
naturally occurring post-translational modifications, which have
been linked to the onset of a number of inflammatory diseases,
autoimmune disorders and are believed to contribute to
oncogenic signaling.[28] Using genetic code expansion strategies
to produce homogeneous proteins featuring these post-transla-
tional modifications could therefore prove valuable in efforts
Figure 3. A) Structures of immunogenic ncAAs. B), C) Principles of breaking self-tolerance via site-selective incorporation of immunogenic ncAAs. B) While
injection of a self-protein in mice does not elicit a strong immune response, C) immunization with an immunogenic ncAA-bearing self-protein results in the
generation of antibodies that show cross-reactivity for the self-protein. D) Structural representation of mTNF-α (PDB ID : 2TNF). α-Carbons of solvent-exposed
residues that were targeted for ncAA incorporation are shown as spheres with color representing the effectiveness of these mutations to elicit cross-reactive
antibodies. E) Summary of survival rates of mice challenged by LPS injection after immunization with relevant mTNF-α variants. F) Structural representation of
mRANKL (PDB ID : 1JTZ). α-Carbons of solvent-exposed residues that were targeted for ncAA incorporation are shown as spheres with color representing the
effectiveness of these mutations to elicit cross-reactive antibodies (color code as in (D)). G) Representative timeline for immunization of mice against OVX-
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aimed at deciphering the biological consequences of formation
of 3NO2Tyr or SO3Phe-bearing neo-epitopes.
2.2. Preventing RANKL-induced bone loss in mice
The TNF cytokine family member RANKL is another self-protein
for which raising cross-reactive antibodies is of clinical interest.
Existing in both membrane-bound and soluble form, RANKL is
an essential factor in the activation of osteoclasts, which are
cells responsible for breaking down the tissue in bones (= bone
resorption).[39] As such RANKL is a therapeutic target for diseases
in which patients suffer from bone erosion caused by an
imbalance in bone remodeling, such as in osteoporosis (OP)
and rheumatoid arthritis (RA).[40] Indeed, the recombinant
monoclonal antibody denosumab, which prevents the activa-
tion of osteoclasts by binding to RANKL, is currently employed
for the treatment of these diseases.[41] Although effective, the
repeated injection of denosumab is also costly, preventing a
more widespread use.
In principle, eliciting cross-reactive antibodies against
RANKL by immunization with ncAA-bearing variants could
provide a cheaper alternative for the treatment of OP and RA.[42]
To enable such developments, Tao et al. produced pNO2Phe-
containig variants of murine RANKL (85 % sequence identity to
human RANKL) and tested their ability to elicit cross-reactive
antibodies for the self-protein following injection into mice.[43]
As it was the case for mTNF-α, the immune response generated
was dependent on the site of mutation (Figure 3F). From the
four positions evaluated, mutations of Tyr234 and Tyr240 gave
rise to high titers of cross-reactive antibodies that persisted in
mice for at least 24 weeks.
The protective potential of pNO2Phe234-mRANKL injection
was evaluated in mouse models for OP and RA. While bone loss
induced in female mice by ovariectomy (OVX) is a common
model for OP,[44] injection of chicken type II collagen results in
collagen-induced arthritis (CIA), which shares several patholog-
ical features with RA.[45] As anticipated, repeated injection of
pNO2Phe234-mRANKL (Figure 3G) reduced the severity of
symptoms both in OVX-induced OP and CIA mice, while
immunization with the self-protein did not have a significant
effect on the progression of either disease.[43,46] Specifically, OVX
mice immunized with the mutant protein showed significantly
reduced bone loss in micro-computed tomography analysis.
Similarly, in the CIA model, immunization with the
pNO2Phe234-mRANKL did not delay the onset of disease, but
the severity of clinical symptoms and joint damage was
significantly decreased when compared to nonimmunized mice.
Together, these results provide proof-of-concept for the
potential of applying immunization with pNO2Phe-bearing
proteins as a potential alternative treatment for RANKL-induced
and related diseases in humans.
3. Live-Attenuated Virus Vaccines
Traditionally, viral vaccines have come in either of two forms: as
inactivated whole virus particles or live-attenuated viruses
(LAVs).[13] Inactivation of viruses is straightforward by heat or
the use of formaldehyde and essentially renders replicating
viruses into inert antigens able to elicit an immune response.
LAVs, on the other hand, contain viruses that remain infective
and able to undergo limited replication upon injection, but
have been sufficiently weakened to not cause damage.[47] Given
that LAVs retain some degree of infectivity, they typically elicit a
stronger immune response than fully inactivated viruses
particles. As such, LAV-based vaccines often provide long-term
protection without booster doses and in some cases can be
administered orally.[17] However, as LAVs maintain their ability
to replicate, they have a low chance to revert to virulence, and
as a result cause the disease they are meant to prevent.[48]
Attenuation of viruses has long been (and often remains) an
empirical process in which an infectious virus is serially
passaged through cell cultures, abnormal hosts and/or below
normal human body temperature (i. e., cold-adapted
attenuation).[9a] The virus gradually weakens as a result of
adapting to these new environments, thereby lowering its
virulence and ability to infect and spread in the intended host.
With the advent of molecular biology, more rational approaches
toward virus attenuation have become available.[49] For exam-
ple, genes encoding for proteins involved in replication or
assembly can be deleted from the viral genome or rendered
inactive by mutation. While resulting viruses are, per se,
replication-incompetent their production remains possible in
cell-lines that express genes encoding for the missing or
dysfunctional proteins. More recently, viral replication has also
been controlled by installing rare codons into viral genomes to
slow the translation of viral proteins (= codon deoptimization)
and by the introduction of microRNAs and zinc finger nucleases
that selectively break down viral RNA.[11,19,29a] Nevertheless, LAVs
created by these means share some of the safety concerns
associated with those based on viruses attenuated through
empirical approaches. Additionally, they often elicit a weaker
immune response than their progenitors and their applicability
can be limited to certain classes of viruses (e. g., RNA viruses or
nonintegrating DNA viruses).
In principle, making viral replication dependent on the
incorporation of ncAAs is a promising strategy for creating LAV-
based vaccines. Instead of deleting or inactivating viral genes,
nonsense codons are introduced as premature termination-
codons (PTCs) at permissive sites throughout the viral genome
(Figure 4A).[23] Introduction of PTCs results in incomplete trans-
lation of viral proteins, thus rendering the virus replication-
incompetent. However, these viruses can be produced in cell
lines which express an OTS that permits readthrough of the
PTC, when its cognate ncAA is supplied. The advantages of this
strategy are threefold: 1) PTC viruses produced in these
transgenic cell lines feature minimal structural deviations when
compared to their progenitor viruses, which is desired for
attaining a high level of infectivity and a strong immune




5ChemBioChem 2020, 21, 1 – 11 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Donnerstag, 30.07.2020


























































incorporating multiple nonsense codons throughout the viral
genome, making reversion to a replication-competent state by
mutation less likely; and 3) the introduction of stop codons to
generate LAVs is possible on the DNA and RNA level and
therefore widely applicable to different classes of viruses.[50] In
the following sections, we highlight the utility of PTC-harboring
viruses for controlling the replication of HIV-1 and for creating
prophylactic and therapeutic vaccines for influenza A.
3.1. Controlling the replication of live-attenuated HIV-1
Since HIV was identified as the causal agent for AIDS in 1983,[51]
major progress in the prevention and treatment of HIV/AIDS
has been made. However, despite continuous efforts, it is
estimated that as of 2018 more than 37 million people are
living with the virus, with 1.7 million people being newly
infected that year.[52] While the development of a successful
vaccine is presumably the only means to control this ongoing
pandemic, this task has proven challenging.[53] Experimental
vaccines that have been developed either do not provide
sufficient levels of protection (e. g., around 30 % in the RV144
efficacy trial)[54] or are not safe enough to be tested in clinical
trials. For example, while deleting the nef gene in simian
immunodeficiency virus resulted in a highly effective LAV
vaccine (>95 % protection in macaques),[55] it also showed
pathogenic potential in animal models.[56] As such, applying
new technologies for the development of safe and effective HIV
vaccines continues to be highly relevant.
Toward this end, Guo and co-workers were the first to apply
genetic code expansion for the construction of replication-
incompetent, PTC-harboring HIV-1.[50a] In a trial-and-error ap-
proach they installed UAG nonsense codons at permissive sites
into a number of HIV-1 genes and tested viral assembly and
infectivity of the resulting PTC viruses. Three structurally similar
tyrosine analogues were tested for the production of PTC-
containing HIV-1 in engineered cell lines featuring matching
OTSs. While p-iodo-l-phenylalanine was not effectively incorpo-
rated in viral proteins and p-acetyl-l-phenylalanine yielded
noninfectious variants, only p-azido-l-phenylalanine (pAzPhe,
Figure 4B) displayed the desired high suppression efficiency
and gave rise to infectious viruses. In addition of PTC-virus
production varying with the choice of ncAA, the viral protein
targeted and the site of mutation proved also crucial, which in
part could be ascribed to the complex nature of HIV-1 gene
splicing and protein processing.[57] While PTC mutations at
various sites in the HIV-1 genome resulted in the pAzPhe-
dependent production of mature HIV-1 in transgenic cells, the
resulting virions often lacked the ability to infect potential host
cells (Figure 4C). Encouragingly though, variants featuring either
one stop codon at position Tyr59 in the gene coding for the
HIV-1 protease (PR) or two PTC mutations at positions Trp36
and Gln127 in the group-specific antigen (gag) protein yielded
infectious viruses in presence of pAzPhe in transgenic cells.
While this study provided proof-of-concept for the creation of a
live PTC viruses, the chance of these HIV-1 strains to regain
functional replication by mutation of the installed nonsense
codon(s) to sense codon(s) raises considerable safety concerns
for their potential application as LAV vaccines.
To decrease the likelihood of PTC HIV-1 variants to revert to
a virulent state, the use of a nonsense quadruplet codon to
encode for a ncAA was explored.[58] For this, an OTS adapted to
decode UAGA codons with Nɛ-(tert-butoxycarbonyl)-l-lysine (Nɛ-
BocLys, Figure 4B) in Escherichia coli could be repurposed for
the incorporation of this ncAA in mammalian (HEK 293T) cells.[59]
To avoid mistranslation of five in-frame UAG-A sequences in the
HIV-1 genome, which could interfere with viral assembly, Guo
and co-workers created an HIV-1 variant that lacked these
Figure 4. A) PTC-harboring viruses can infect and replicate upon addition of a ncAA in transgenic cell lines that feature an OTS specific for this ncAA.
Conversely, PTC viruses remain the infective for the intended host cells but cannot propagate in the absence of the OTS and ncAA. B) Structures of ncAAs
used for the construction of PTC-harboring HIV-1. C) Infectivity of PTC-harboring HIV-1 viruses created by incorporating ncAAs at different sites in viral
proteins. D) Replication of PTC-harboring HIV-1 can be controlled by the addition of ncAAs if an OTS is introduced at a permissive site in the HIV genome. E)
Structure of Nɛ-AzELys, which was used to create PTC-harboring influenza A viruses. F) Schematic representation of nucleic acids found inside the influenza A
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sequences and displayed replication and infectivity levels
comparable to the parent strain. Introducing Nɛ-BocLys by
suppression of UAGA codons at the previously identified
positions Tyr59 in PR or Trp36 in gag gave rise to infectious
HIV-1 virions, although at significantly lower levels than the
parent variant. A theoretically lower escape frequency of these
HIV-1 variants results from the fact that reversion of the + 1
frameshift caused by the incorporation of the quadruplet codon
requires a deletion event, which is rare compared to simple
point mutations that can revert UAG-harboring PTC viruses.[60]
Lastly, another point of concern for replication-incompetent
PTC-harboring viruses is that immunization with a single
infection cycle HIV virus would likely result in an insufficient
immune response.[61] To clear this hurdle, Guo et al. generated a
PTC-harboring HIV-1 mutant, for which genes encoding for the
OTS for decoding UAG with Nɛ-BocLys were inserted at a
permissive site in the viral genome.[62] Consequently, the
replication of this mutant could be controlled in conventional
cell lines by simply supplementing Nɛ-BocLys into the media
(Figure 4D). Unfortunately, the infectivity of the resulting PTC-
harboring virus was significantly lower than for the parent HIV-
1, presumably due to the low expression levels of the OTS
components. Nevertheless, this type of PTC-harboring virus
could potentially allow for controlling HIV-1 replication by co-
administering the ncAA, thus keeping the virus infective until a
sufficiently strong immune response is elicited.
3.2. Toward prophylactic and therapeutic influenza A
vaccines
Yearly, worldwide influenza outbreaks result on average in
about 3–5 million cases of severe illness and >300.000
deaths.[63] Rendering the influenza viruses responsible for this
loss of life into avirulent vaccines while maintaining sufficient
infectivity remains challenging.[64] Attenuated influenza viruses
do in principle match these criteria, but immune escape due to
antigenic drift and shift adds to the challenges associated with
creating effective vaccines against seasonal influenza viruses.[65]
With the aim of providing a more robust alternative to available
attenuated vaccines, Zhuo and co-workers set out to create
PTC-harboring influenza A strains that could reproduce exclu-
sively in transgenic cell lines and subsequently be used for
prophylactic and therapeutic vaccination.[50b]
To allow for the production of PTC-harboring influenza A
viruses, a HEK293T cell line was constructed with an OTS for Nɛ-
2-azidoethyloxycarbonyl-l-lysine (Nɛ-AzELys, Figure 4E). Trans-
fection of this packaging cell line with the genome of an
influenza strain featuring a UAG codon at a randomly chosen
site (Asp101 in the nucleoprotein, NP) indeed resulted in the
reproduction and correct packaging of influenza A virions
(Figure 4F). Critically, no virus production was observed in a
conventional cell line upon infection with the progeny virus,
which contrasts results obtained for cold-adapted live attenu-
ated influenza vaccine (CAIV) and codon-deoptimized influenza
A viruses which both showed residual infectivity and
reproductivity.[66] Moreover, introduction of PTCs proved a
general strategy, as for eight different influenza proteins at least
one site for mutation was identified that resulted in high
packaging and propagation efficiency. Aware of mutation of
the UAG codon being a straightforward escape mechanism for
PTC-harboring viruses, influenza A strains harboring 1 to 8
nonsense codons in different viral proteins were constructed
(Figure 4F). These viruses retained good packaging efficiencies
(at least 67 % compared to the wild-type), while showing escape
frequencies over 20 passages ranging from 10  2 to 10  9 for
variants featuring one nonsense codon to <10  11 (below the
detection limit in the assay) for those harboring more than
three stop codons.
To evaluate the in vivo safety of PTC-harboring influenza A
strains, PTC-4a was selected as none of its four mutations were
in envelope genes, thus providing wild-type-like representation
of surface antigens. Following injection of PTC-4a at 100.000
times the median lethal dose (LD50) of the parent influenza
strain, no mice succumbed or showed any symptoms associated
with influenza infection (i. e., body weight loss or other health
issues). Moreover, lower viral titers were elicited after injection
of PTC-4a not only compared to the wild-type virus, but also to
a CAIV, further underling its overall safety in vivo. Similarly,
when guinea pigs inoculated with PTC-4a were caged together
with non-infected ones, no transmission was detected, which
again contrasts results obtained for wild-type viruses or CAIV,
where transmission was readily observed. Thus, these experi-
ments demonstrate the overall safety of PTC-harboring influen-
za viruses.
Besides showing high levels of safety, PTC-4a was also able
to elicit a strong immune response when injected into mice,
ferrets or guinea pigs. In fact, this replication-incompetent
influenza A virus not only gave rise to robust antibodies in
serum (humoral immunity), but also to high level of secretory
immunoglobulin A in the lungs (mucosal immunity) and
cytotoxic T lymphocytes (cell-mediated immunity). Notably, the
levels for all three elicited immune effectors were boosted
significantly upon a second injection of PTC-4a and overall
comparable to those levels elicited by CAIV. Furthermore, the
protective efficacy of PTC-4 A virus was high: when challenged
with 50 times the LD50 of the wild-type virus, all mice survived
after immunization even with just one dose of PTC-4a, with
injection of two doses preventing any symptoms associated
with influenza infection. The strong immune response elicited
provided also significant protection, when mice were chal-
lenged with antigenically distant influenza strains. Such heterol-
ogous protection was ascribed to surface and internal antigens
that are highly conserved among distant influenza strains and
to a broad protective effect of influenza-specific of cytotoxic T-
lymphocytes.[67]
Lastly, somewhat counterintuitively, co-injection of PTC-4a
and wild-type influenza A into mice resulted in reduction of
viral titers when measured over the following days. This
inhibition of the wild-type virus by PTC-4a cannot be ascribed
to acquired immunity, but results from attenuation by genetic
reassortment between the PTC-harboring virus and the wild-
type.[65,68] Upon infecting the same host cell, genes are being
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become replication incompetent when they are packaged with
at least one PTC-harboring gene (Figure 5). Sequencing analysis
of propagated viruses confirmed the creation of an assortment
of replication-incompetent PTC-harboring influenza strains.
Notably, the attenuation effect was directly proportional to the
number of PTCs introduced, with a variant featuring four or
more UAG stop codons essentially preventing proliferation of
wild-type influenza in vitro. Combined, these experiments
indicate that viruses harboring multiple PTCs could not only
find use in the prophylactic prevention of viral diseases, but
also applied as therapeutic vaccines for the neutralization of
replicating viruses.
4. Challenges and Future Prospects
The proof-of-concept studies highlighted in this review attest
on the future applicability of genetic code expansion strategies
for the development of protein- and LAV-based vaccines. For
the former, the incorporation of ncAAs such as pNO2Phe into
self-proteins provides a straightforward means to break self-
tolerance and elicit a robust humoral immune response.
Similarly, the production of LAVs by introduction of PTCs has
proven effective for containing viral replication in vitro and
in vivo.
The precise control over the site and number of introduced
ncAAs into nonimmunogenic proteins makes suppression of
nonsense codons a promising strategy for creating protein-
based vaccines. Their potential for inducing immunity against
self-proteins makes the technique a promising tool for creating
sought-after therapeutic vaccines against inflammatory diseases
and different types of cancer.[69] In addition to the development
of vaccines against self-proteins, this strategy could potentially
find application for eliciting immune response against patho-
gen-associated proteins that are not or weakly immunogenic.
While the results obtained for self-proteins are promising, the
fact that the formation of cross-reactive antibodies was depend-
ent on the genetic background of mice in genes encoding for
MHC class-II molecules is problematic. The genetic variability of
MHC genes in the population[70] and the difficulty of under-
standing and predicting T-cell specificity for particular
peptides[71] are important hurdles to overcome for these
protein-based vaccines to become applicable for treating
human diseases. Therefore, more systematic studies on reliably
identifying possible site(s) of modification in proteins and the
development of OTSs for more immunogenic ncAAs, such as
Nɛ-dinitrophenylacetyl-l-lysine)
[72] and three halotyrosine
residues[73] could prove valuable for furthering the development
of immunogenic self-proteins. Lastly, the ability to generate
homogenous self-proteins that feature naturally occurring,
stress-induced post-translational modifications could provide
useful insights for elucidating mechanisms of activation and
progression of autoimmune disorders as well as cancer. This
information could further unveil which modifications generate
an immunogenic epitope and therefore expand the applicability
of incorporating ncAAs for the development of vaccines.
Creating LAVs by making viral replication dependent on the
presence of an OTS and a matching ncAA could be widely
applicable to develop vaccines for different viruses. Especially
for viruses for which attenuation using conventional methods is
challenging (e. g., herpes simplex virus),[74] a straightforward
means to create replication-incompetent variants should be of
particular interest. Thus far however, approaches for identifying
suitable incorporation sites for ncAAs have largely been trial-
and-error and their effect on virus assembly and infectivity was
not always straightforward to interpret. Complex processing of
viral genomes and proteins leading up to assembly of full
virions (e. g., for retroviruses) complicates finding permissive
sites for PTC incorporation.[75] Thus, other virus classes likely
provide better targets for development of PTC-harboring LAVs,
as demonstrated for influenza A. In addition to further exploring
the consequences of incorporating PTCs into viral genomes for
the generation of infective virions, the resulting LAVs must also
undergo a rigorous validation with respect to their safety
in vivo. Intriguingly, the incorporation of PTCs into genomes
might also be applicable for the development of vaccines
against persistent infectious diseases caused by bacterial
pathogens. Specifically, multiple studies have recently suc-
ceeded to make bacterial survival strictly dependent on the
presence of a ncAA and a matching OTS (synthetic
biocontainment).[23,76] Adapting these biocontainment strategies
to bacterial pathogens – note that the ncAA incorporation in
Mycobacterium tuberculosis has previously been reported[77] –
could pave the way toward the creation of infective pathogens
that can only replicate in engineered cell lines. Lastly, to
prevent reversion to replicating pathogens in host by mutation
of introduced nonsense codons, essential enzymes of the
pathogens could be engineered to make their function depend
on the incorporation a ncAA.[78]
Overall, we are confident that future studies will continue to
highlight and further progress the utility of genetic code
expansion for vaccine development.
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Figure 5. Principles of genetic reassortment. Co-injection of wild-type and
PTC-4a slows viral replication due to the formation of an assortment of
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